Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
April 2017
-
Media ReleaseNovartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MSOver 16 months, more than 75% of patients on Gilenya had either no relapses, no new or enlarged MRI lesions or no disability progression; around 58% showed brain shrinkage levels broadly within the…
-
Media ReleaseSandoz proposed biosimilars rituximab and etanercept recommended for approval in Europe*Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Biosimilar rituximab also recommended to treat blood cancers Comprehensive…
-
Media ReleaseNIH study in NEJM shows Novartis drug eltrombopag as first-line therapy with standard treatment improves responses in severe aplastic anemiaNIH study found 58% of patients with treatment-naïve severe aplastic anemia (SAA) achieved a complete response when eltrombopag was given at the initiation of and concurrently with standard…
-
Media ReleaseNovartis expands development programs for NASH through clinical collaboration with AllerganPhase IIb clinical trial to evaluate a combination of a Novartis FXR agonist and Allergan's cenicriviroc for NASH, a progressive form of non-alcoholic fatty liver disease There are…
-
Media ReleaseNovartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCLDesignation prioritizes investigational CTL019 (tisagenlecleucel) as a potential treatment for adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) R/r DLBCL…
-
Women in Science: Medy Attalla
-
The specter of malaria that resists treatment
Great progress has been made against malaria, but signs of resistance are becoming a rising concern
-
Media ReleaseNovartis to strengthen R&D pipeline by in-licensing ECF843 for ophthalmic indicationsNovartis exercises an option to in-license ECF843, a recombinant form of human lubricin from Lubris LLC, for ophthalmic indications worldwide (outside Europe) Dry eye is an area with high unmet…
-
Loss of friend to liver cancer sharpens focus on experimental therapy
A Novartis experimental drug in clinical trial aims to block liver cancer growth
-
Media ReleaseNovartis drug combination Tafinlar® + Mekinist® receives EU approval for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC Approval based on data showing more than 60% overall response rate…
March 2017
-
Women in Science: Annie Martin
Our Global Head of Precision Medicine in Oncology discusses her day-to-day work at Novartis.
-
Media ReleaseNovartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority ReviewPriority review for investigational CTL019 (tisagenlecleucel-T), a novel therapy that is manufactured for each individual patient using their own T cells Novartis made an early commitment to the…
Pagination
- ‹ Previous page
- 1
- …
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- …
- 152
- › Next page